P-034PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2nd July 2019) - Muro, K; Uetake, H; Tsuchihara, K; Shitara, K; Yamazaki, K; Ota, M; Oki, E; Sato, T; Naitoh, T; Komatsu, Y; Kato, T; Yamanaka, K; et al.